Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target
VRTX Analyst Ratings
Strong Buy
22Buy3Hold0Sell
Based on 25 analysts giving stock ratings to Vertex Pharmaceuticals in the past 3 months
VRTX Stock 12 Month Forecast
Average Price Target
MXN 11,074.37▲(9.32% Upside)Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is MXN 11,074.37 with a high forecast of MXN 12,530.29 and a low forecast of MXN 8,303.43. The average price target represents a 9.32% change from the last price of MXN 10,130.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighMXN 12.53K
AverageMXN 11.07K
LowMXN 8.3K
Highest Price TargetHighestMXN 12,530.29Average Price TargetMXN 11,074.37Lowest Price TargetLowestMXN 8,303.43
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | Citi | MXN 10,989.84 | buy | 8.49%Upside | Reiterated | 10/27/26 | ||
| David Risinger | Leerink Partners | ― | buy | ― | Reiterated | 10/27/26 | ||
| Michael Yee | UBS | MXN 11,553.42 | buy | 14.05%Upside | Assigned | 10/26/26 | ||
| Tazeen Ahmad | Bank of America Securities | MXN 12,530.29 | buy | 23.69%Upside | Reiterated | 10/26/26 | ||
| Andrew Fein | H.C. Wainwright | MXN 12,041.86 | buy | 18.87%Upside | Reiterated | 10/26/26 | ||
| Phil Nadeau | TD Cowen | MXN 10,332.33 | buy | 2.00%Upside | Assigned | 10/26/26 | ||
| Louise Chen | Scotiabank | MXN 10,482.61 | buy | 3.48%Upside | Reiterated | 10/26/26 | ||
| Carter Gould | Cantor Fitzgerald | MXN 11,177.70 | buy | 10.34%Upside | Reiterated | 10/25/26 | ||
| Salveen Richter | Goldman Sachs | MXN 12,267.29→MXN 12,286.07 | buy | 21.28%Upside | Reiterated | 10/25/26 | ||
| Mohit Bansal | Wells Fargo | MXN 10,332.33 | buy | 2.00%Upside | Reiterated | 10/15/26 | ||
| Evan Seigerman | BMO Capital | MXN 11,271.63 | buy | 11.27%Upside | Reiterated | 10/12/26 | ||
| Brian Abrahams | RBC Capital | MXN 10,708.05→MXN 10,820.76 | buy | 6.82%Upside | Reiterated | 10/08/26 | ||
| Terence Flynn | Morgan Stanley | MXN 12,492.72 | buy | 23.32%Upside | Assigned | 10/07/26 | ||
| Jeffrey Walch | Bernstein | MXN 11,421.92 | buy | 12.75%Upside | Reiterated | 09/25/26 | ||
| Eliana Merle | Barclays | MXN 11,590.99 | buy | 14.42%Upside | Reiterated | 09/23/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | 10/27/26 | MXN 10,989.84 | buy | 8.49%Upside | Reiterated | Citi | ||
| David Risinger | 10/27/26 | ― | buy | ― | Reiterated | Leerink Partners | ||
| Michael Yee | 10/26/26 | MXN 11,553.42 | buy | 14.05%Upside | Assigned | UBS | ||
| Tazeen Ahmad | 10/26/26 | MXN 12,530.29 | buy | 23.69%Upside | Reiterated | Bank of America Securities | ||
| Andrew Fein | 10/26/26 | MXN 12,041.86 | buy | 18.87%Upside | Reiterated | H.C. Wainwright | ||
| Phil Nadeau | 10/26/26 | MXN 10,332.33 | buy | 2.00%Upside | Assigned | TD Cowen | ||
| Louise Chen | 10/26/26 | MXN 10,482.61 | buy | 3.48%Upside | Reiterated | Scotiabank | ||
| Carter Gould | 10/25/26 | MXN 11,177.70 | buy | 10.34%Upside | Reiterated | Cantor Fitzgerald | ||
| Salveen Richter | 10/25/26 | MXN 12,267.29→MXN 12,286.07 | buy | 21.28%Upside | Reiterated | Goldman Sachs | ||
| Mohit Bansal | 10/15/26 | MXN 10,332.33 | buy | 2.00%Upside | Reiterated | Wells Fargo | ||
| Evan Seigerman | 10/12/26 | MXN 11,271.63 | buy | 11.27%Upside | Reiterated | BMO Capital | ||
| Brian Abrahams | 10/08/26 | MXN 10,708.05→MXN 10,820.76 | buy | 6.82%Upside | Reiterated | RBC Capital | ||
| Terence Flynn | 10/07/26 | MXN 12,492.72 | buy | 23.32%Upside | Assigned | Morgan Stanley | ||
| Jeffrey Walch | 09/25/26 | MXN 11,421.92 | buy | 12.75%Upside | Reiterated | Bernstein | ||
| Eliana Merle | 09/23/26 | MXN 11,590.99 | buy | 14.42%Upside | Reiterated | Barclays |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Vertex Pharmaceuticals
3 Months
Success Rate26/35 ratings generated profit
74%
Average Return
+8.06%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 74.29% of your transactions generating a profit, with an average return of +8.06% per trade.
1 Year
Success Rate20/25 ratings generated profit
80%
Average Return
+14.44%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +14.44% per trade.
2 Years
Success Rate40/40 ratings generated profit
100%
Average Return
+26.00%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +26.00% per trade.
VRTX Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 50 | 59 | 70 | 62 | 37 |
| Hold | 9 | 9 | 9 | 6 | 2 |
| Sell | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 60 | 69 | 80 | 68 | 39 |
In the current month, VRTX has received 37 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 11,074.37.
VRTX Financial Forecast
HighMXN 98.66
ConsensusMXN 90.52
LowMXN 69.15
VRTX Earnings Forecast
Next quarter’s earnings estimate for VRTX is MXN 90.52 with a range of MXN 69.15 to MXN 98.66. The previous quarter’s EPS was MXN 88.89. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 65.8B
ConsensusMXN 64.2B
LowMXN 62.6B
VRTX Sales Forecast
Next quarter’s sales forecast for VRTX is MXN 64.24B with a range of MXN 62.58B to MXN 65.82B. The previous quarter’s sales results were MXN 62.84B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
VRTX Stock Forecast FAQ
What is MX:VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is Mex$11,074.37.
What is MX:VRTX’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 9.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Vertex Pharmaceuticals a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 22 buy ratings, 3 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s share price target?
The average share price target for Vertex Pharmaceuticals is Mex$11,074.37. This is based on 25 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$12,530.29, and the lowest forecast is Mex$8,303.43. The average share price target represents a 9.32% increase from the current price of Mex$10,130.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Street analysts.
How can I buy shares of Vertex Pharmaceuticals?
To buy shares of MX:VRTX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.